Current Editions

Age at onset and delivery route may shape where cyclodextrin therapies fit in NPC

AI’s clearest near-term gains, and its next frontier in drug development: The BioCentury Show

Via deal with China-based Alebund, the well-funded start-up is developing a therapy that could challenge phosphate binders in hyperphosphatemia

With three T cell engager platforms and a trispecific in the clinic, the Shanghai-based biotech raises $68.7M in seed funding

Oral GLP-1R agonist aleniglipron delivers up to 16.3% placebo-adjusted weight loss and will advance to Phase III

Plus: engineered receptors to target low-CD70 solid tumors, Xaira’s virtual cell model, and infectious disease company innovations

The newly approved pill from Protagonist and J&J narrows the efficacy gap with injectables

With support from Republican committee chairs, the FDA commissioner has side-stepped Congress

After months-long lapse, critical early-stage funding program reauthorized

Deal for mutation-selective molecule comes more than a year after Lilly’s purchase of Scorpion for breast cancer asset in same class

Plus: Crossbow lines up its first shot in the clinic, and new rounds for Mestag, Unnatural Products, R1 and Excalipoint

Plus: The week’s PIPEs, follow-ons, and IPOs